益生菌联合艾普拉唑四联疗法治疗幽门螺杆菌感染的临床研究

Clinical study of probiotics combined with eprazole quadruple therapy in the treatment of helicobacter pylori infection

目的:分析益生菌联合艾普拉唑四联疗法治疗幽门螺杆菌(HP)感染的临床研究。方法:选取2016年3月—2021年3月本院HP感染患者100例,按随机数字表法分为研究组(n=50)和对照组(n=50),对照组以予艾普拉唑肠溶片餐前口服,5 mg/次,2次/d;枸橼酸铋钾颗粒餐前口服,220 mg/次,2次/d;阿莫西林胶囊餐后口服,1000 mg/次,2次/d;呋喃唑酮片餐后口服,100 mg/次,2次/d。研究组在对照组用药基础上给予双歧杆菌四联活菌片餐前口服,1.5 g/次,3次/d,双歧杆菌四联活菌片与抗菌药物服药时间至少间隔2 h。两组均治疗14 d。比较两组疗效、治疗前后临床症状积分及不良反应发生率。结果:研究组总有效率94.00%(47/50)较对照组的74.00%(37/50)高(P<0.05);治疗前,两组临床症状积分比较无显著差异(P>0.05),治疗后,两组临床症状积分均较治疗前降低,且研究组低于对照组(P<0.05);研究组不良反应发生率为6.00%(3/50),较对照组的30.00%(15/50)低(P<0.05)。结论:益生菌联合艾普拉唑四联疗法治疗HP感染患者可提高疗效,减轻肌体炎症反应,改善临床症状,并可降低不良反应,安全性更高。

Objective:To analyze the clinical study of probiotics combined with eprazole tetraplex therapy in the treatment of helicobacter pylori(HP)infection.Methods:100 patients with HP infection in our hospital from March 2016 in March 2021 were randomly divided into the study group(n=50)and the control groups(n=50).The control group was treated with eprazole tetraplex therapy(eprazole enteric tablets,oral administration before meals,5 mg/times,2 times/d;potassium bismuth citrate particles,oral administration before meals,220 mg/time,2 times/d;amoxicillin capsules,oral administration after meals,1000 mg/time,2 times/d;fufurazololone tablets,oral administration after meals,100 mg/time,2 times/d).On the basis of the control group,the study group was given probiotics(bifidobacterium tetralive tablets),oral administration before meal,1.5 g/time,3 times/d.The interval between bifidobacterium tetralive tablets and antimicrobial medication was at least two hours.Both groups were treated for 14 days.The efficacy,the integration of clinical symptoms before and after treatment,and the incidence of adverse reactions in both groups were compared before and after treatment.Results:The total effective rate was 94.00%(47/50)in the study group,which was higher than 74.00%(37/50)in the control group(P<0.05).Before treatment,there was no significant difference in clinical symptom scores between the two groups(P>0.05).After treatment,the clinical symptom scores were lower than those before treatment,and the study group was lower than those in the control group(P<0.05).The incidence of adverse reactions in the study group was 6.00%(3/50),which was lower than 30.00%(15/50)in the control group(P<0.05).Conclusion:Probiotics combined with iprazole tetraplex therapy in the treatment of patients with HP infection can improve efficacy,reduce the inflammatory response,improve clinical symptoms,reduce adverse reactions,and have higher safety.